APA (7th ed.) Citation

TD, P., JH, B., AE, M., N, M., C, S., DJ, B., & HG, M. (2024). Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma. BMC cancer, 24(1), 1562. https://doi.org/10.1186/s12885-024-13334-y

Chicago Style (17th ed.) Citation

TD, Pham, Becker JH, Metropulos AE, Mubin N, Spaulding C, Bentrem DJ, and Munshi HG. "Regorafenib Induces DNA Damage and Enhances PARP Inhibitor Efficacy in Pancreatic Ductal Carcinoma." BMC Cancer 24, no. 1 (2024): 1562. https://doi.org/10.1186/s12885-024-13334-y.

MLA (9th ed.) Citation

TD, Pham, et al. "Regorafenib Induces DNA Damage and Enhances PARP Inhibitor Efficacy in Pancreatic Ductal Carcinoma." BMC Cancer, vol. 24, no. 1, 2024, p. 1562, https://doi.org/10.1186/s12885-024-13334-y.